1 s e p t e m b e r 2 0 1 6 | V O L 5 3 7 | N A t U r e | 1 1 7 2+ interacts directly with one subunit and blocks the pore. In contrast, the phenylalkylamine Br-verapamil binds in the central cavity of the pore on the intracellular side of the selectivity filter, physically blocking the ion-conducting pathway. Structure-based mutations of key amino-acid residues confirm drug binding at both sites. Our results define the structural basis for binding of dihydropyridines and phenylalkylamines at their distinct receptor sites on Ca V channels and offer key insights into their fundamental mechanisms of action and differential therapeutic uses in cardiovascular diseases.
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Ca
2+ antagonist drugs are widely used in therapy of cardiovascular disorders 1,2 . Three chemical classes of drugs bind to three separate, but allosterically interacting, receptor sites on Ca V 1.2 channels, the most prominent voltage-gated Ca 2+ (Ca V ) channel type in myocytes in cardiac and vascular smooth muscle [3] [4] [5] [6] [7] [8] [9] . The 1,4-dihydropyridines are used primarily for treatment of hypertension and angina pectoris and are thought to act as allosteric modulators of voltage-dependent Ca 2+ channel activation, whereas phenylalkylamines and benzothiazepines are used primarily for treatment of cardiac arrhythmias and are thought to physically block the pore 1,2 . The structural basis for the different binding, action, and therapeutic uses of these drugs remains unknown. Here we present crystallographic and functional analyses of drug binding to the bacterial homotetrameric model Ca V channel Ca V Ab, which is inhibited by dihydropyridines and phenylalkylamines with nanomolar affinity in a state-dependent manner. The binding site for amlodipine and other dihydropyridines is located on the external, lipid-facing surface of the pore module, positioned at the interface of two subunits. Dihydropyridine binding allosterically induces an asymmetric conformation of the selectivity filter, in which partially dehydrated Ca 2+ interacts directly with one subunit and blocks the pore. In contrast, the phenylalkylamine Br-verapamil binds in the central cavity of the pore on the intracellular side of the selectivity filter, physically blocking the ion-conducting pathway. Structure-based mutations of key amino-acid residues confirm drug binding at both sites. Our results define the structural basis for binding of dihydropyridines and phenylalkylamines at their distinct receptor sites on Ca V channels and offer key insights into their fundamental mechanisms of action and differential therapeutic uses in cardiovascular diseases.
Ca V 1 channels are composed of a complex of a pore-forming α 1 subunit associated with β , γ , and α 2δ subunits 1, 10 . The α 1 subunits contain four homologous domains with six transmembrane segments in each 11, 12 . Transmembrane segments S1-S4 form the voltage-sensing module, and S5, S6 and the intervening P-loop form the pore 1 . The overall architecture of the mammalian skeletal muscle Ca V 1.1 channel was recently elucidated at a resolution of ~ 4-6 Å by cryoelectron microscopy 13 . However, higher-resolution structural analysis of mammalian Ca V channels has not yet been achieved. The bacterial voltage-gated Na + channel NaChBac and its relatives are homotetrameric proteins composed of four identical subunits, each analogous to one domain of a mammalian voltage-gated Na + or Ca 2+ channel 14, 15 . These bacterial channels probably represent the evolutionary ancestors of both mammalian channel families. The structures of bacterial Na + channels have been determined at high resolution by X-ray crystallography in pre-open 16 and inactivated 17, 18 states. Moreover, the structural basis for Ca 2+ conductance and selectivity has been elucidated at atomic resolution through studies of Ca V Ab, a site-directed mutant of Na V Ab with full Ca 2+ channel function 19 . We have used derivatives of Ca V Ab (see Methods) to define receptor sites and mechanisms of action of Ca 2+ antagonist drugs at atomic resolution. Ca V Ab was inhibited by amlodipine with high affinity (Fig. 1a-c) . No inhibition was observed during single depolarizations, indicating that amlodipine does not enter the open pore and block it (Fig. 1a) . However, inhibition increased progressively during trains of depolarizations, reflecting increased binding affinity for the activated and/or inactivated states of Ca V Ab (Fig. 1b) . After a train of 20 depolarizing pulses, the half-maximum inhibitory concentration (IC 50 ) for inhibition by amlodipine was 10 nM (Fig. 1c) . This affinity was surprisingly high, considering the evolutionary distance between Ca V Ab and mammalian Ca V 1.2 channels, which have IC 50 values from 0.3 nM to 1 μ M for various dihydropyridines 20 . Photoaffinity labelling and site-directed mutagenesis suggest that dihydropyridines bind to a receptor site at the interface of homologous domains III and IV and the adjacent pore module in domain III in Ca V 1.2 channels [4] [5] [6] [7] 21, 22 . In Ca V Ab, four identical subunits form a homotetramer (Fig. 1d) 
19
. The structure of the amlodipine-Ca V Ab complex reveals the antagonist bound on the outer, lipid-facing surface of the pore module in the intersubunit crevice formed by neighbouring tilted S6 helices and the P-helix of the selectivity filter (Fig. 1d , e, yellow sticks). Despite the homotetrameric structure of Ca V Ab, only a single drug-binding site per tetramer is occupied, suggesting that drug-induced conformational changes prevent occupancy of more than one site. Amino-acid residues Y195, I199, F171, Y168 and F167 form a hydrophobic pocket for interaction with amlodipine (Fig. 1f) . The dihydropyridine ring is sandwiched between Y195 of S6 and F167 of the P-loop. F171 and I199 of S6 form the bottom of the cleft that accommodates the bound drug. Mutations of I199 (for example, I199S) had minimal effects on Ca V Ab function (Extended Data Fig. 1 ), but markedly reduced the affinity for amlodipine (IC 50 = 112 nM; Fig. 1c) .
Nimodipine inhibited Ca V Ab like amlodipine, but its IC 50 was 100 nM (Fig. 2a-c) . Nimodipine binds to the same site as amlodipine (Fig. 2d , e and Extended Data Fig. 2a, b) . The substitution I199S increased the IC 50 for nimodipine from 100 nM to 5.7 μ M (Fig. 2c) , and W195Y increased it to 508 nM (Extended Data Fig. 3 ). The experimental Br-dihydropyridine derivative UK-59811 inhibited Ca V Ab with IC 50 = 194 nM (Extended Data Fig. 4 ) and bound in a similar position ( Fig. 2f and Extended Data Fig. 2a, c) . Anomalous scattering density from its Br atom further confirmed the location of the dihydropyridine-binding site at the interface between the S6 segments of two adjacent subunits surrounded by Y195, F171, F167, and I199 (Fig. 2f, green mesh) . High-resolution structures of Ca V Ab revealed 16 molecules of bound lipid per tetramer 19 . Without drugs, we found a single molecule of DMPC lipid aligned in the dihydropyridine-binding pocket with its polar headgroup facing the extracellular side and its long hydrocarbon tails projecting deep into the crevice formed by neighbouring S6 helices ( Fig. 2g and Extended Data Fig. 2d ). Thus, our In the absence of dihydropyridines, the Ca V Ab structure has fourfold symmetry around the pore axis 19 . Four lipid molecules are found in the central cavity, occupying fenestrations that connect to the exterior of the channel (Fig. 3a) . Binding of dihydropyridines to Ca V Ab rearranges the quaternary structure and breaks the fourfold symmetry (Fig. 3c , e, g, compare shaded cross-sections; see Supplementary Discussion of asymmetry induced by drug binding). With drug bound, the four lipid molecules in the central cavity lose their symmetric spatial organization, and the fenestration closest to the drug-binding site is no longer occupied by a lipid chain.
By introducing asymmetry, dihydropyridine binding triggers allosteric changes at the selectivity filter of Ca V Ab and alters binding of the substrate ion. There are three Ca 2+ -binding sites in the Ca V Ab selectivity filter: two high-affinity sites (Sites 1 and 2) followed by one lower-affinity site (Site 3) arranged sequentially from its extracellular to intracellular end 19 . Without drug, Ca 2+ binds near the central axis of the pore in a fully hydrated state, coordinated symmetrically by four D178 carboxylate side chains (Fig. 3b) 
. With dihydropyridines bound, Ca 2+ binds to Site 1 asymmetrically in a partially dehydrated state-significantly off the central axis of the pore and closer to one or two D178 carboxylate groups at a distance of 2.8-3.3 Å (Fig. 3d , f, h and Extended Data Fig. 5a-d ). This binding distance suggests direct interaction of bound Ca 2+ with the carboxylate side chain (Supplementary Discussion). In contrast, binding of Ca 2+ at Site 2 is unchanged (data not shown). The anomalous scattering density of Ca 2+ confirms its off-axis location in Site 1 and on-axis location in Site 2 (Extended Data Fig. 5e, f) .
Studies with quaternary phenylalkylamine analogues revealed that these drugs inhibit Ca V 1.2 channels only after cytoplasmic application, and that drug binding is increased by repetitive depolarization to open the pore 2, 23 . It was therefore concluded that tertiary phenylalkylamines such as verapamil penetrate the membrane in uncharged form, are re-protonated in the cytosol, and block the Ca V 1.2 channel by entering the intracellular mouth of the open pore in their protonated form and binding to their receptor site 2, 23 . Photoaffinity labelling and site-directed mutagenesis revealed that the phenylalkylamine receptor site is formed by S6 segments in domains III and IV of Ca V 1.2 channels, consistent with drug binding in the pore [4] [5] [6] [7] 24, 25 . When Br-verapamil was perfused at − 120 mV, the first depolarization to 0 mV showed progressive reduction of the current during the pulse (Fig. 4a) . This profile supports a pore-blocking mechanism, in which the drug progressively enters and blocks the open pore. Repetitive depolarizing stimuli increased inhibition of Ca V Ab by Br-verapamil (Fig. 4b) , yielding IC 50 values of 810 nM for Br-verapamil (Fig. 4c , blue squares) and 475 nM for verapamil (Extended Data  Fig. 6a, b) at steady state. The action of these drugs is strikingly statedependent: the IC 50 for Br-verapamil in the resting state is 24 μ M, 30-fold higher than observed after a train of depolarizing stimuli (Fig. 4c, blue circles) .
Our crystal structures revealed a single molecule of Br-verapamil bound in the central cavity on the intracellular side of the ion selectivity filter ( Fig. 4d, e ; see Supplementary Discussion of asymmetry induced by drug binding). The bound drug is oriented with its characteristic positively charged tertiary amino group facing in the extracellular direction pointing towards Site 3 in the selectivity filter. In this position, the bound phenylalkylamine would physically block the pore. The distance between the tertiary amino group and Ca 2+ coordinated by the carbonyls of L176 is 5 Å. The methoxy groups in the aromatic rings are located close to the inner end of the fenestrations, surrounded by T206, M209 of the neighbouring subunit and T175, M174, L176 of the selectivity filter (Fig. 4f) . The two aromatic rings of Br-verapamil interact with T206 residues from two neighbouring S6 helices (Fig. 4f) . A view from the intracellular side shows that Br-verapamil binds closer to two subunits on one side of the pore (Fig. 4f) . The anomalous scattering from Br-verapamil further defines the position of the aromatic ring that is farther from the amino group and confirms its interaction with T206 (Fig. 4e, green mesh) . Mutations in T206 impair inactivation of Ca V Ab (Extended Data Fig. 6c, e) and markedly reduce the affinity for Br-verapamil. For example, the conservative mutation T206S increases the IC 50 for state-dependent inhibition from 810 nM to 24 μ M (Fig. 4c , red squares) and the IC 50 for resting state inhibition of Ca V Ab from 24 μ M to 115 μ M (Fig. 4c, red circles) . The effects of these mutations on both resting and state-dependent block confirm that there is a direct interaction between the drug and T206. These results define the receptor site for pore block by phenylalkylamines at high resolution. Similar to the dihydropyridine-binding site, the phenylalkylamine-binding site is also occupied by lipid molecules in the absence of the drug.
At concentrations above 1 μ M, dihydropyridines inhibit voltagegated Na + channels in a manner consistent with pore block 26 . At the high drug concentrations used in our crystallization studies, we found binding of UK-59811 (Fig. 4g-i ) and other dihydropyridines in the pore of Ca V Ab. The anomalous scattering density of its Br places the dihydropyridine ring deep in the central cavity where it forms hydrophobic contacts with two neighbouring subunits (Fig. 4h, green  mesh) . Compared to Br-verapamil, UK-59811 bound more towards the intracellular base of the central cavity and was located closer to one subunit ( Fig. 4g-i) . Low-affinity block of Na + channels by dihydropyridines bound in this site may contribute to cardiac arrhythmias caused by toxic overdoses of these drugs.
Overall, our results provide a structural basis for understanding how dihydropyridines and phenylalkylamines bind at two distinct, but allosterically coupled receptor sites on Ca V 1.2 channels and have different efficacy for treatment of hypertension and angina pectoris versus cardiac arrhythmias [1] [2] [3] [5] [6] [7] . Consistent with photoaffinitylabelling and site-directed mutagenesis [5] [6] [7] , dihydropyridines bind on the outer, lipid-facing surface of the pore module at the interface between two subunits of Ca V Ab, in analogy with their proposed site of action between domains III and IV of Ca V 1.2 channels 4, 21 . Their binding site is exposed to the extracellular side of the membrane, but not to the intracellular side. These structural results reveal why charged dihydropyridines are ineffective when applied intracellularly 27 , and they are consistent with location of the drug-binding site ~ 11-14 Å from the outer surface of the lipid bilayer as inferred from studies of charged derivatives of amlodipine with hydrophobic linkers of increasing length 28 . These comparisons reveal a close analogy between the site of dihydropyridine binding in our crystal structures of Ca V Ab and the expectations from studies of Ca V 1.2 channels, but the exact position of the drug-binding site in Ca V Ab is approximately one helical turn towards the extracellular side from the amino-acid residues implicated in dihydropyridine binding by studies of Ca V 1.2 channels (Extended Data Fig. 7) . This difference may reflect the great evolutionary distance between Ca V Ab and mammalian Ca V channels and/or indirect allosteric effects of mutations studied in Ca V 1 channels.
Binding of a single dihydropyridine to Ca V Ab induces a conformational change that alters the fourfold symmetry of the quaternary structure and induces changes in the three unoccupied dihydropyridinebinding sites that may prevent drug occupancy (Extended Data Fig. 8 ). Drug binding also disrupts the symmetry of the ion selectivity filter, allowing direct coordination of Ca 2+ by carboxylate side chains. This conformational change is mediated in part by an altered pattern of hydrogen bonds formed by N181 in the subunit binding the dihydropyridine (Fig. 3) . These structural results correlate closely with ligand-binding studies of Ca V 1.2 channels, which suggested that dihydropyridines induce high-affinity Ca 2+ binding and block of the pore 29, 30 . Our structural studies reveal exactly how dihydropyridines act as indirect allosteric blockers of the pore of Ca 2+ channels. Dihydropyridine binding to Ca V 1.2 channels is voltage-dependent because of the high affinity for the inactivated state 1, [5] [6] [7] . In a remarkable parallel, dihydropyridine binding causes a conformational change to an asymmetric pore structure in Ca V Ab, which is similar to the asymmetry induced in inactivated states of the parent Na V Ab channel 17 and its relative Na V Rh 18 . Dihydropyridine binding may induce a similar asymmetric, Ca 2+ -blocked state of Ca V 1.2 channels and thereby enhance their inactivation, allowing selective inhibition in persistently depolarized cells. This mechanism underlies the use of dihydropyridines in treatment of hypertension and angina pectoris, in which vascular smooth muscle cells of resistance vessels are persistently depolarized, and their Ca V 1.2 channels are selectively inhibited by dihydropyridines.
The phenylalkylamine receptor site was localized to the S6 segments in domains III and IV of Ca V 1.2 channels by photoaffinity labelling and mutational analysis, and it was proposed that the amino-acid side chains involved in drug binding point towards the lumen of the [4] [5] [6] 24, 25 . Our structural results correlate precisely with this expectation and reveal the exact structure of the drug-receptor complex. Br-verapamil is stretched between two subunits of Ca V Ab, consistent with drug binding at the interface of domains III and IV in Ca V 1.2 channels 4-6,24,25 . As for dihydropyridines, phenylalkylamine binding at this site disrupts the fourfold symmetry of the pore (Extended Data Fig. 9) . Location of the phenylalkylamine receptor site deep in the central cavity in the pore reveals why binding of these drugs is state-dependent. Access of phenylalkylamines to their receptor is greatly enhanced by opening the intracellular activation gate, which allows diffusion to the drug receptor site. Drug binding is therefore frequency-dependent, allowing selective block of Ca V 1.2 channels in rapidly firing cardiac myocytes 2 . This mechanism is the basis for use of verapamil for cardiac arrhythmias.
Overall, our structural studies illuminate the complex pharmacology and therapeutic uses of Ca 2+ antagonist drugs in treatment of different cardiovascular disorders at the atomic level (see Supplementary Discussion). These structural models will be important for design and development of next-generation Ca 2+ antagonist drugs to provide safer and more effective treatment of hypertension, angina pectoris, cardiac arrhythmia, and other medical conditions.
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Ca V Ab constructs and drugs. As originally defined, Ca V Ab was constructed by introducing the mutations E177D, S178D and M181D as a triple mutant into Na V Ab 19 . This construct was used for all electrophysiological studies, except as noted in figure legends. In this work, we have also used Ca V Ab E177D S178D M181N, which has an identical structure and Ca
2+
-binding properties and has high Ca 2+ selectivity 19 . It gives greater consistency of high-resolution crystal structures. We have also added the mutation W195Y, which substitutes the Y residue from the analogous position in mammalian Ca V 1.1 channels for W195 in Ca V Ab. This mutant gives better resolution of drugs bound at the dihydropyridine site. Ca V Ab E177D S178D M181N W195Y was used for all structural studies presented here, except as noted in the figure legends. Similar structural results were obtained for both versions of Ca V Ab. We found that amlodipine and other dihydropyridines (Figs. 1 and 2 and Extended Data Figs 1, 3 and 4 ) and verapamil and other phenylalkylamines (Fig. 4 and Extended Data Fig. 6 ) effectively blocked Ca V Ab and gave high-resolution crystal structures; however, we were unable to prepare crystals with bound diltiazem for structural biology so we have not addressed the structure of the benzothiazepine receptor site in this work. Electrophysiology. All measurements were done in insect cells (Trichoplusia ni cells; High5). All Ca V Ab constructs used were made on the background of N49K mutation. Mutation N49K shifts the activation curve ~ 75 mV to more positive potentials compared to wild-type Ca V Ab and abolishes the use-dependent inactivation as described previously 19, 31 . All constructs showed good expression, allowing measurement of ionic currents 24-48 h after infection. Whole-cell Ba 2+ currents were recorded using an Axopatch 200 amplifier (Molecular Devices) with glass micropipettes (2-4 MΩ ). Capacitance was subtracted and 80-90% of series resistance was compensated using internal amplifier circuitry. Extracellular solution contained in (mM) 10 ] total = 13 mM). Intracellular solution contained in (mM) 105 CsF, 35 NaCl, 10 HEPES, 10 EGTA, (pH 7.4, adjusted with CsOH). Current-voltage (I-V) relationships were recorded in response to steps to voltages ranging from −120 to + 50 mV in 10-mV increments from a holding potential of − 120 mV. Conductance-voltage (G-V) curves were calculated from the corresponding (I-V) curves. Pulses were generated and currents were recorded using Pulse software controlling an Instrutech ITC18 interface (HEKA). Data were analysed using Igor Pro 6.2 (WaveMetrics). Sample sizes were chosen to give s.e.m. values of less than 10% of peak values based on prior experimental experience. Inhibition curves were fit with a Hill equation with n H = 1.0 unless indicated otherwise in the figure legends. Protein expression and purification. The pFastBac-Flag-Ca V Ab was used as the construct for producing homotetrameric model voltage-gated Ca 2+ channel 19 . I199S, W195Y, and T206S constructs were generated via site-directed mutagenesis using QuickChange (Stratagene). Recombinant baculovirus were produced using the Bac-to-Bac system (Invitrogen), and T. ni insect cells were infected for large-scale protein purification. Cells were harvested 72 h post-infection and resuspended in buffer A (50 mM Tris-HCl, pH = 8.0, 200 mM NaCl) supplemented with protease inhibitors and DNase. After sonication, digitonin (EMD Biosciences) was added to 1%, and solubilization was carried out for 1-2 h at 4 °C. Clarified supernatant was then incubated with anti-Flag M2-agarose resin (Sigma) for 1-2 h at 4 °C with gentle mixing. Flag-resin was washed with ten column volumes of buffer B (buffer A supplemented with 0.12% digitonin) and eluted with buffer B supplemented with 0.1 mg ml −1 Flag peptide. The eluant was concentrated and then passed over a Superdex 200 column (GE Healthcare) in 10 mM Tris-HCl pH = 8.0, 100 mM NaCl and 0.12% digitonin. The peak fractions were concentrated using a Vivaspin 30K centrifugal device. Crystallization and data collection. Ca V Ab and the W195Y mutant were concentrated to ~ 20 mg ml −1 and reconstituted into DMPC:CHAPSO (Anatrace) bicelles according to standard protocols 16, 17, 32, 33 . The protein-bicelle preparation and a well solution containing 1.8-2.0 M ammonium sulphate, 100 mM Na-citrate pH = 5.0 was mixed in 1:1 ratio and set up in a hanging-drop vapour-diffusion format. All the antagonist complex crystals were obtained through co-crystallization by incubating the protein-bicelle with 100 μ M antagonist overnight before setting up crystallization trials. For the UK-59811 complex, both 100 μ M and 200 μ M antagonist were used for UK-59811/Ca V Ab crystals. Crystals were cryoprotected by soaking in 0.1 M Na-acetate, pH 5.0, 26% glucose, 2.0 M ammonium sulphate, and 5 mM Ca
. Crystals were plunged into liquid nitrogen and maintained at 100 K during all data collection procedures.
The anomalous diffraction data sets for Br were collected at 0.9194 Å, and the anomalous data sets for Ca 2+ were collected at 1.75 Å with the same synchrotron radiation source (Advanced Light Source, BL8.2.1). To optimize the anomalous scattering signal, the data sets were collected by using the 'inverse beam strategy' with the wedge size of 5°.
Structure determination, refinement, and analysis. X-ray diffraction data were integrated and scaled with the HKL2000 package 34 and further processed with the CCP4 package 35 . The structure of Ca V Ab and its antagonist complex were solved by molecular replacement using an individual subunit of the Ca V Ab structure (PDB code 4MS2) as the search template. The data sets were processed in P21221 space group, in which there are four molecules in one asymmetric unit. Crystallography and NMR System software 36 were used for refinement of coordinates and B-factors. Final models were obtained after several cycles of refinement with REFMAC 37 and PHENIX 38 plus manual re-building using COOT 39 . The geometries of the final structural models of Ca V Ab and its antagonist complexes were verified using PROCHECK 40 . Divalent cations were identified by anomalous difference Fourier maps calculated using data collected at wavelengths of 1.75 Å for Ca 2+ . The Br atoms of UK-59811 and Br-verapamil were identified by anomalous difference Fourier maps calculated using data collected at wavelengths of 0.9194 Å. Procedures accounting for merohedral twinning were performed during structural refinement of amlodipine, nimodipine, and Br-verapamil data sets. Detailed crystallographic data and refinement statistics for all constructs are shown in Extended Data Table 1 . All structural figures were prepared with PyMol 41 . 
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